COGT — Cogent Biosciences, Inc. stock price, charts and financials

Latest market price

42.84

+3.98+10.24%

Overview Short InterestFilings

COGTQT63Cogent Biosciences, Inc.·NASDAQ

Overview Short InterestFilings

42.84+10.24%

Earnings

Up 10.2% — Reported earnings — EPS in line.

High confidence

Loading chart...

Screen all →

IBRX-2.80%$6.95 RYTM+2.92%$105.78 TGTX+5.57%$48.74 PCVX+2.17%$54.69 IMVT+2.21%$39.36 APGE+0.06%$134.19 ALKS+0.28%$49.67 ERAS+3.03%$18.38

Snapshot

Index	-	P/E	-	EPS (ttm)	-3.04	Insider Own	-	Shs Outstand	170.87M	Perf Week	5.34%

Market Cap	7.32B	Forward P/E	-	EPS next Y	-0.77	Insider Trans	-7.64%	Shs Float	148.52M	Perf Month	8.62%

Enterprise Value	6.69B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	11.15%	Perf Quarter	16.63%

Income	-23.00M	P/S	-	EPS this Y	26.15%	Inst Trans	-	Short Ratio	6.89	Perf Half Y	12.86%

Sales	24.00M	P/B	12.04	EPS next Y	65.57%	ROA	-39.24%	Short Interest	16.56M	Perf YTD	20.61%

Book/sh	3.56	P/C	8.45	EPS next 5Y	-	ROE	-83.29%	52W High	43.73 -2.04%	Perf Year	275.79%

Cash/sh	5.07	P/FCF	-	EPS past 3/5Y	-	ROIC	-42.77%	52W Low	10.38 312.72%	Perf 3Y	237.06%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	6.83% 4.91%	Perf 5Y	587.64%

Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-23.58%	Oper. Margin	0.00%	ATR (14)	2.04	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	15.14	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	63.54	Recom	2.17

Dividend Gr. 3/5Y	-	Current Ratio	15.14	EPS Q/Q	-1.92%	SMA20	8.21%	Beta	0.34	Target Price	46.75

Payout	0.00%	Debt/Eq	0.40	Sales Q/Q	-	SMA50	16.32%	Rel Volume	1.92	Prev Close	38.86

Employees	258	LT Debt/Eq	0.39	Earnings	Aug 04	SMA200	22.45%	Avg Volume	2.47M	Price	42.84

IPO Date	Mar 29, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.49% -	Net Debt/EBITDA	0.01	Volume	4,748,555	Change	10.24%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-01-26	Reiterated	Stifel Nicolaus		$40 → $45
May-06-26	Reiterated	HC Wainwright & Co.	Buy	$52 → $55
Feb-19-26	Reiterated	Robert W. Baird		$34 → $35
Feb-18-26	Reiterated	Piper Sandler	Overweight	$52
Jan-07-26	Reiterated	UBS		$60
Jan-06-26	Reiterated	HC Wainwright & Co.	Buy	$14 → $52
Dec-08-25	Reiterated	Jefferies	Buy	$45 → $48
Nov-11-25	Reiterated	Raymond James		$30 → $60
Nov-10-25	Reiterated	Stifel Nicolaus		$16 → $40
Nov-10-25	Reiterated	Wedbush	Neutral	$38

Latest News

Jul-28-26

Jul-28-2610:00AM

Cogent Biosciences (NASDAQ:COGT) Shows Perfect Breakout Setup with Top Technical StrengthChartMill

Jul-19-26

Jul-19-2603:10AM

Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q1 2026 UpdateSeekingAlpha

Jun-30-26

Jun-30-2608:04AM

Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Advanced Systemic MastocytosisBenzinga

08:00AM

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)globenewswire.com

Jun-14-26

Jun-14-2609:13AM

Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage LeverageSeekingAlpha

Jun-13-26

Jun-13-2601:00AM

Cogent Biosciences, Inc. (COGT) Presents at European Hematology Association (EHA) 2026 Congress - SlideshowSeekingAlpha

Jun-12-26

Jun-12-2608:03AM

Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European Hematology Association Congress, June 11-14Benzinga

Company

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	24	0	0	0	0	0	8	22	10
Cost of Goods Sold Incl. D&A	34	5	0	0	0	0	26	0	0
Gross Profit	-11	-5	0	0	0	0	-18	22	10
Selling, General and Administrative Excl. Other	13	64	43	34	26	20	17	11	7
Research and Development	34	270	233	174	122	56	73	44	38
Other Operating Expense	-24	-5	0	0	0	0	-26	0	1
Operating Income	-23	-333	-276	-208	-148	-76	-82	-32	-36
Interest Expense	0	3	0	0	4	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	0	7	20	16	12	3	7	0	1
Net Income Before Taxes	-23	-329	-256	-192	-140	-72	-75	-32	-35
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-23	-329	-256	-192	-140	-72	-75	-30	-35
Net Income From Continuing Operations	-23	-329	-256	-192	-140	-72	-75	-32	-35
Net Income	-23	-329	-256	-192	-140	-72	-75	-30	-35
EPS (Recurring)	-3.04	-2.55	-2.46	-2.42	-2.26	-1.85	-6.00	-3.97	-5.55
EPS (Basic, Before Extraordinaries)	-3.04	-2.55	-2.46	-2.42	-2.26	-1.85	-6.00	-3.97	-5.55
EPS (Diluted)	-3.04	-2.55	-2.46	-2.42	-2.26	-1.85	-6.00	-3.97	-5.55
EBITDA	-22	-321	-252	-189	-130	-70	-35	-31	-35
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	14.28	—	—	—	—	—	15.44	1.05	10.56
Gross Margin	-45.83	—	—	—	—	—	-225.00	100.00	100.00
Operating Margin	-95.83	—	—	—	—	—	-1,025.00	-145.45	-360.00
Net Margin	-95.83	—	—	—	—	—	-937.50	-136.36	-350.00
Shares Outstanding	8	68	104	80	59	39	11	8	6
Market Capitalization	343	2,415	811	470	682	335	124	23	106
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fairmount Funds Management LLC	Director	Mar 31 '26	Sale	34.66	7,000,000	242,620,000	5,503,418	Mar 31
Fairmount Funds Management LLC	Director	Jan 22 '26	Sale	36.40	3,500,000	127,400,000	5,503,418	Jan 22
Robinson John Edward	Chief Scientific Officer	Dec 26 '25	Sale	38.74	90,000	3,486,600	140,002	Dec 30
Sachs Jessica	Chief Medical Officer	Dec 26 '25	Sale	38.70	82,642	3,198,245	133,938	Dec 30
Green John L.	Chief Financial Officer	Dec 26 '25	Sale	38.68	77,000	2,978,360	131,834	Dec 30
Kearns Evan	Chief Legal Officer	Dec 26 '25	Sale	38.70	65,000	2,515,500	109,398	Dec 30
Fairmount Funds Management LLC	Director	Jul 10 '25	Buy	9.00	2,777,777	24,999,993	9,003,418	Jul 14
Pinnow Cole	Chief Commercial Officer	Jan 14 '25	Buy	7.60	43,750	332,413	45,848	Jan 15
Fairmount Funds Management LLC	Director	Jun 10 '24	Option Exercise	0.00	1,501,500	1,500	6,225,641	Jun 12
Fairmount Funds Management LLC	10% Owner	Jun 09 '23	Buy	12.00	800,000	9,600,000	3,272,124	Jun 13
Fairmount Funds Management LLC	director:	Jun 16 '22	Buy	8.25	1,200,000	9,900,000	2,472,124	Jun 21
Green John L.	Chief Financial Officer	Apr 26 '21	Sale	8.86	35,626	315,646	3,841	Apr 28
CAMPANA DARIO	10% Owner	May 12 '20	Sale	0.46	98,200	45,545	3,095,114	Oct 08
CAMPANA DARIO	10% Owner	May 11 '20	Sale	0.46	100,000	45,496	3,193,314	Oct 08
CAMPANA DARIO	10% Owner	May 08 '20	Sale	0.46	100,000	46,390	3,293,314	Oct 08

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.